NCT00034606已完成2 期
Comparing 3 Schedules of Alimta Plus Gemzar
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 1
研究概览
简要总结
The purpose of the study is to measure tumor response rates for three schedules of Alimta(LY231514) in combination with gemcitabine in patients with locally advanced or metastatic non small cell lung cancer who have received no prior chemotherapy regimen.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of non-small lung cancer
- •No prior chemotherapy
- •Able to care for self
排除标准
- •An ongoing infection
- •Pregnancy or breast feeding
- •Other serious medical condition
- •Cancer that has spread to the brain
- •Inability to take folic acid
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.Pancreatic NeoplasmsMetastases, NeoplasmNCT00035035Eli Lilly and Company
已完成
3 期
A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung CancerNon Small Cell Lung CarcinomaNCT00087711Eli Lilly and Company1,713
终止
2 期
Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal CancerPeritoneal CancerOvarian CancerNCT00055432Eli Lilly and Company
终止
2 期
Pemetrexed and Gemcitabine Every 14 Days Versus Every 21 Days in Advanced Non Small Cell Lung CancerNon-Small-Cell Lung CancerNCT00383331Eli Lilly and Company19
已完成
3 期
Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the CervixCancer of CervixNCT00191100Eli Lilly and Company515